Ampio Pharmaceuticals, Inc.
AMPE · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.04 | 0.01 | -0.00 |
| FCF Yield | -136.36% | -18.96% | -97.91% | -66.28% |
| EV / EBITDA | 0.96 | 2.22 | 1.94 | 1.50 |
| Quality | ||||
| ROIC | -58.75% | -22.45% | -21.19% | -51.64% |
| Gross Margin | 100.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.12 | 0.45 | 2.48 | 0.58 |
| Growth | ||||
| Revenue 3-Year CAGR | 625,632.47% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -316.04% | 83.67% | -47.72% | 46.41% |
| Safety | ||||
| Net Debt / EBITDA | 1.72 | 4.31 | 4.17 | 2.33 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 337.96 | 0.00 | 0.00 | 0.00 |